Maximizing the Value of Foreign Collaborations While Safeguarding U.S. Investments
The National Institutes of Health (NIH), the nation’s primary medical research agency, recently issued guidance on the use of international subcontractors in NIH-funded research. This announcement reflects NIH’s dual mission: advancing health outcomes for Americans while ensuring responsible stewardship of U.S. taxpayer dollars. While global collaborations remain critical to accelerating biomedical progress, NIH’s new principles emphasize the need for scientific justification, accountability, and tangible domestic benefit from any research conducted abroad.
Overview of the Guidance
NIH highlights that it is not a foreign aid organization; rather, its investments in research must deliver both scientific and taxpayer value. To that end, NIH has established a set of guiding principles for international research subcontracting. All projects performed outside the U.S. must demonstrate a clear scientific rationale for why the work cannot be done domestically. Moreover, foreign-based research must directly contribute to understanding, improving, or protecting the health of Americans.
Equally important, NIH highlights the imperative of financial transparency and risk management. Misuse of funding or resources is a significant concern, and the agency stresses the importance of knowing precisely where every dollar goes and to whom. NIH makes clear that international collaborations will be pursued only when the benefits are apparent and the risks are manageable.
Compliance Risks
For organizations including foreign subcontractors in NIH proposals, the updated guidance introduces new compliance challenges. Below are key risks:
- Weak Justification for Foreign Work
- Lack of Transparency in Subcontractor Finances
- Insufficient Oversight of Subcontractor Performance
- Data Security and Intellectual Property Concerns
- Misalignment with NIH’s U.S. Health Priorities
EverGlade’s Best Practices
For organizations pursuing NIH funding that involve international partners, aligning with these new principles will be critical. Demonstrating both the scientific necessity of foreign collaborations and their direct benefit to U.S. health outcomes will strengthen applications. EverGlade Consulting specializes in helping research institutions and companies navigate such evolving federal requirements. When navigating this funding landscape EverGlade helps you:
- Clearly document why the research must be performed outside the U.S. (for example, access to unique patient populations, specialized facilities, or local expertise not available domestically).
- Establish robust reporting mechanisms, including itemized budgets, regular financial statements, and independent audits where possible.
- Define measurable milestones, prepare frequent progress reports, and implement monitoring protocols for international and domestic subcontractors.
- Negotiate clear data-sharing agreements with subcontractors upfront, ensure compliance with U.S. data protection laws, and use secure IT systems for sensitive research data.
- Explicitly link the foreign research outputs to U.S. public health benefits in the proposal narrative and ensure this alignment is reinforced in all progress reports.
Why This Matters
NIH’s updated stance reinforces the principle that while science is global, NIH’s responsibility is first to the American people. This guidance will influence how universities, research institutions, and industry partners structure collaborations with foreign entities. Stronger oversight and clearer justification requirements will shape proposal strategies, compliance processes, and post-award management for years to come.
NIH’s guidance serves as a reminder that global collaboration remains a powerful driver of discovery, yet it must be pursued with careful accountability. If your company has considered applying for federal funding, your federal funding journey starts here. EverGlade Consulting is a national firm that helps organizations win and manage federal awards. We offer services ranging from Pursuit, Proposal and Post-Award support to comply with federal regulations at agencies including BARDA, ARPA-H, NIH, DTRA, JPEO, DOD, DIU, DOE, and DARPA.
